Both scenarios are of potential neuropathogenic interest (Suarez et al., 2018), and early treatment with inhibitors of retrotranscription approved by the United States Food and Drug Administration (New drugs for HIV infection, 1996) might mitigate consequences of FOXG1 gain-of-function mutations. This evidence concerns the gene FOXG1 and HIV infectious disease.